TY - JOUR
T1 - Advances in the Treatment of Non–small Cell Lung Cancer
T2 - Focus on Nivolumab, Pembrolizumab, and Atezolizumab
AU - Leventakos, Konstantinos
AU - Mansfield, Aaron S.
N1 - Publisher Copyright:
© 2016, Springer International Publishing Switzerland.
PY - 2016/10/1
Y1 - 2016/10/1
N2 - Immunotherapy is revolutionizing the treatment of non–small cell lung cancer (NSCLC). Immune checkpoint inhibitors, including programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) monoclonal antibodies, are being introduced to routine clinical practice. This review summarizes clinical trials of nivolumab, pembrolizumab, and atezolizumab in patients with NSCLC. These agents have efficacy against NSCLC and a unique toxicity profile. The role of PD-L1 as a predictive biomarker is still unclear, partially because of the nuances of PD-L1 testing. These novel therapies also challenge our existing methodologies of radiologic assessment and efficacy analysis. This new era of immunotherapy has ushered in as much hope for patients as questions from physicians that need to be answered to clarify the optimal use of these agents.
AB - Immunotherapy is revolutionizing the treatment of non–small cell lung cancer (NSCLC). Immune checkpoint inhibitors, including programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) monoclonal antibodies, are being introduced to routine clinical practice. This review summarizes clinical trials of nivolumab, pembrolizumab, and atezolizumab in patients with NSCLC. These agents have efficacy against NSCLC and a unique toxicity profile. The role of PD-L1 as a predictive biomarker is still unclear, partially because of the nuances of PD-L1 testing. These novel therapies also challenge our existing methodologies of radiologic assessment and efficacy analysis. This new era of immunotherapy has ushered in as much hope for patients as questions from physicians that need to be answered to clarify the optimal use of these agents.
UR - http://www.scopus.com/inward/record.url?scp=84978087340&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84978087340&partnerID=8YFLogxK
U2 - 10.1007/s40259-016-0187-0
DO - 10.1007/s40259-016-0187-0
M3 - Review article
C2 - 27411930
AN - SCOPUS:84978087340
SN - 1173-8804
VL - 30
SP - 397
EP - 405
JO - BioDrugs
JF - BioDrugs
IS - 5
ER -